Skip to main content

Table 1 Patient Characteristics (N = 12)

From: A prospective phase I dose-escalation trial of stereotactic ablative radiotherapy (SABR) as an alternative to cytoreductive nephrectomy for inoperable patients with metastatic renal cell carcinoma

Characteristic

Value

Age at diagnosis – median (range)

66.8 (55.0–85.1)

Male – n (%)

7 (58.3)

Laterality – n (%)

 Left Kidney

4 (33.3)

 Right Kidney

8 (66.7)

Histology – n (%)

 Clear Cell

9 (75)

 Papillary

2 (16.7)

 Othera

1 (8.3)

Location of Metastasesb

 Lung

10 (83.3)

 Bone

6 (50)

 Lymph nodes

5 (41.7)

 Brain

3 (25)

 Otherc

4 (33.3)

Karnofsky Performance Status – median (range)

70 (40–90)

Karnofsky Performance Status – n (%)

 ≥ 80%

5 (41.7)

 <  80%

7 (58.3)

IMDC Prognostic Group – n (%)

 Favorable

1 (8.3)

 Intermediate

8 (66.7)

 Poor

3 (25)

Systemic Therapy Timingb – n (%)

 

 None

6 (50)

 Pre-SABR

1 (8.3)

 Post-SABR

4 (33.3)

 Both

1 (8.3)

Systemic Therapy Type – n (%)

 None

6 (50)

 Pazopanib or Sunitinib

5 (41.7)

 Temsirolimus or Everolimus

2 (16.7)

SABR Treatment Technique – n (%)

 VMAT

7 (58.3)

 TOMO

5 (41.7)

Dose Cohort (Gy) – n (%)

 25/5

3 (25)

 30/5

6 (50)

 35/5

3 (25)

Primary tumor sized (cm) – median (range)

8.7 (4.8–13.8)

Actuarial median follow-up (months)e - median (95% CI)

22 (4.63, N/A)

  1. IMDC: International Metastatic Renal Cell Carcinoma Database Consortium, SABR: stereotactic ablative radiotherapy, CI: confidence interval, TOMO: helical tomotherapy, IMRT: intensity modulated radiotherap. aPoorly-differentiated carcinoma (n = 1); bCategories not mutually-exclusive; cKidney (n = 1), liver (n = 2), left adrenal (n = 1); dLongest tumor dimension on CT scan; eReverse Kaplan-Meier Method